These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21182344)

  • 1. The cost of managing HIV infection in highly treatment-experienced, HIV-infected adults in France.
    Colin X; Lafuma A; Costagliola D; Lang JM; Guillon P
    Pharmacoeconomics; 2010; 28 Suppl 1():59-68. PubMed ID: 21182344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden.
    Ghatnekar O; Hjortsberg C; Gisslén M; Lindbäck S; Löthgren M
    Pharmacoeconomics; 2010; 28 Suppl 1():49-57. PubMed ID: 21182343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.
    Hill AM; Gebo K; Hemmett L; Löthgren M; Allegri G; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():169-81. PubMed ID: 21182350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France.
    Colin X; Lafuma A; Costagliola D; Smets E; Mauskopf J; Guillon P
    Pharmacoeconomics; 2010; 28 Suppl 1():183-97. PubMed ID: 21182351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study.
    Erb P; Battegay M; Zimmerli W; Rickenbach M; Egger M
    Arch Intern Med; 2000 Apr; 160(8):1134-40. PubMed ID: 10789606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.
    Hill AM; Clotet B; Johnson M; Stoll M; Bellos N; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():69-81. PubMed ID: 21182345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
    Ruof J; Dusek A; DeSpirito M; Demasi RA
    Clin Drug Investig; 2007; 27(7):469-79. PubMed ID: 17563127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of disease stage on direct medical costs of HIV management: a review of the international literature.
    Levy A; Johnston K; Annemans L; Tramarin A; Montaner J
    Pharmacoeconomics; 2010; 28 Suppl 1():35-47. PubMed ID: 21182342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of changes in CD4 count and HIV RNA during the first six months on highly active antiretroviral therapy in chronic human immunodeficiency virus infection.
    Ormaasen V; Bruun JN; Sandvik L; Holberg-Petersen M; Gaarder PI
    Scand J Infect Dis; 2003; 35(6-7):383-8. PubMed ID: 12953949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral drug costs and prescription patterns in British Columbia, Canada: 1996-2011.
    Nosyk B; Montaner JS; Yip B; Lima VD; Hogg RS;
    Med Care; 2014 Apr; 52(4):362-9. PubMed ID: 24848208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis.
    Bendavid E; Wood R; Katzenstein DA; Bayoumi AM; Owens DK
    J Acquir Immune Defic Syndr; 2009 Sep; 52(1):106-13. PubMed ID: 19448557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.
    Sloan CE; Champenois K; Choisy P; Losina E; Walensky RP; Schackman BR; Ajana F; Melliez H; Paltiel AD; Freedberg KA; Yazdanpanah Y;
    AIDS; 2012 Jan; 26(1):45-56. PubMed ID: 22008655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hospitalizations and costs of treatment for protease inhibitor-based regimens in patients with very advanced HIV-infection (CD4 < 50/mm(3)).
    Floridia M; Massella M; Bucciardini R; Perucci CA; Rossi L; Tomino C; Fragola V; Ricciardulli D; Galluzzo CM; Giannini G; Pirillo MF; Andreotti M; Mirra M; Vella S
    HIV Clin Trials; 2000; 1(2):9-16. PubMed ID: 11590493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
    Brogan A; Mauskopf J; Talbird SE; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.
    Bratt G; Karlsson A; Leandersson AC; Albert J; Wahren B; Sandström E
    AIDS; 1998 Nov; 12(16):2193-202. PubMed ID: 9833861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.